Shukra Pharma Bags Rights for Wockhardt Anti-Infectives

One of the global pharmaceutical companies, Wockhardt Ltd., has signed and empowered Shukra Pharmaceuticals Limited to be the agent, distributor and manager for the evolved anti-infective products of their entire range all over the country. The deal includes the distribution of ESIC/ESIS Hospitals, Defence Hospitals, and AFMSD/DGAFMS units in all locations in India.

Shukra Pharmaceuticals made an announcement that it has taken up the responsibility of a strategic non-exclusive Pan-India distribution Partner with Wockhardt.EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin) are the two main components of the portfolio, which contain pure and high-tech anti-infective products. 

Both of them are antibacterials on which international researchers have been able to rely in order to write up the novel approach to severe infections. These pharmaceuticals have been formulated to follow the demand trend for new solutions in institutional and government healthcare networks.

Also Read: Navin Fluorine Launches cGMP-4 Plant at Dewas

Shukra Pharma emphasized that their partnership with them would be a game changer for their stature and visibility not only in the stable sectors of the health care but also in the revenue and operational domains. They indicated that the collaboration is expected to be the source of innovation and growth for the stakeholders by bringing together the hospital and healthcare infrastructure to meet India’s increasing demand.

Giving his point of view on the progress, Shukra Pharma declared that this comes as a bold move that mirrors its pledge to support the advanced healthcare solutions arena while also unearthing the market potential for unmet medical needs all over the country. Shukra Pharmaceuticals Limited is a producer and merchant of pharmaceutical products and also offers specialized laboratory testing services.